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Abstract
Objective—Characterize responses to a NNRTI-based antiretroviral treatment (ART) initiated
during acute HIV infection (AHI).
Design—This was a prospective, single-arm evaluation of once daily, co-formulated
emtricitabine/tenofovir/efavirenz initiated during AHI.
Methods—The primary endpoint is the proportion of responders with HIV RNA <200 copies/mL
by week 24. We examined time-to-viral-suppression and CD8 cell activation in relation to
baseline participant characteristics. We compared time-to-viral-suppression and viral dynamics
using linear mixed effects models between acutely infected participants and chronically-infected
controls.
Results—Between January 2005 and May 2009, 61 AHI participants were enrolled. Of
participants whose enrollment date allowed 24 and 48 weeks of follow-up, 47 of 51 (92%)
achieved viral suppression to <200 copies/mL by week 24, and 35 of 41 (85.4%) to <50 copies/
mL by week 48. The median time from ART initiation to suppression <50 copies/mL was 93 days
(range 14–337). Higher HIV RNA levels at ART initiation (p=0.02), but not time from estimated-
date-of-infection to ART initiation (p=0.86), were associated with longer time-to-viral-
suppression. The median baseline frequency of activated CD8+CD38+HLA-DR+ T-cells was
67% (range 40–95), and was not significantly associated with longer time to viral load suppression
(p=0.15). Viremia declined to <50 copies/mL more rapidly in AHI than chronically-infected
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participants. Mixed model analysis demonstrated similar phase I HIV RNA decay rates between
acute and chronically-infected participants, and more rapid viral decline in acutely-infected
participants in phase II.
Conclusion—Once daily emtricitabine/tenofovir/efavirenz initiated during AHI achieves rapid
and sustained HIV suppression during this highly infectious period.
Keywords
Acute HIV infection; NNRTIs; antiretroviral therapy; immune activation; viral dynamics
Introduction
Antiretroviral therapy (ART) initiated during acute HIV infection (AHI) remains
controversial and incompletely characterized. Amidst this controversy, the benefit of ART
as a prevention method has been difficult to explore despite evidence that a significant
proportion of ongoing HIV transmission is related to AHI [1]. Since transmission is most
strongly associated with plasma HIV RNA levels [2–5], very high viremia demonstrated
during AHI markedly increases the likelihood for sexual transmission during this phase. A
significant proportion of sexual transmission is driven by AHI, [6–9] with results from
Uganda suggesting up to 43% of incident HIV is transmitted by acutely-infected individuals
[7]. Virions circulating during AHI are genetically very similar to the infectious founder
virus[10] and may also be highly infectious regardless of copy number [11].
Identifying individuals with AHI represents a critical opportunity to avert substantial onward
transmission [12, 13] through secondary prevention efforts to modify high-risk behaviors
[14], and possibly through ART initiation during this highly infectious period. While
modeling studies suggest that treating a substantial proportion of HIV-infected individuals
could curtail the HIV epidemic [15], the identification of acutely-infected individuals
followed by rapid, efficacious treatment and retention-in-care may be essential if ART is to
impact the spread of HIV.
Despite a lack of adequately powered studies to demonstrate sustained and measurable
clinical or immunological benefit of ART in AHI, ART is sought by many acutely-infected
individuals and recommended for consideration by some experts [16, 17]. Based upon
higher prevalence of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance in
treatment naïve patients [18], guidelines favor protease inhibitor (PI)-based regimens in AHI
(DHHS guidelines, 2008). However, since ART failure associated with pill and adherence
fatigue ranks among leading concerns with ART use in AHI, rapid initiation of the simplest
fixed-dose combination (FDC) therapy which can be modified once genotype data are
available warrants investigation in this setting. In addition to adherence advantages with
once-daily, FDC tenofovir, emtricitabine and efavirenz (Atripla©) used in this study,
efavirenz-based regimens have demonstrated superiority to some PI-based regimens in
naïve, chronically-infected patients and more rapid viral suppression [19]. Clinicians face
balancing the benefits of rapid initiation of uncomplicated therapy with initiating more
cumbersome therapy or the costs of the delay to ensure the most appropriate therapy based
on resistance testing.
We characterized immunologic and virologic responses to a once-daily, NNRTI-based
regimen initiated during AHI. Since activation of CD8+ cells has been associated with HIV
disease pathogenesis [20, 21], we also characterized levels of CD8+CD38+HLADR+ cell
activation during AHI and determined if levels were associated with time-to-viral-
suppression. We compared HIV RNA dynamics following initiation of efavirenz-based ART
between participants with AHI and chronically-infected individuals. Our primary goal was
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to demonstrate that we could identify acutely-infected individuals, promptly administer
simple, effective ART with minimal consequences due to transmitted drug resistance,
rapidly suppress HIV-1 and retain patients in care.
Methods
This study is a single-arm evaluation of once daily, FDC emtricitabine, tenofovir and
efavirenz administered to AHI participants enrolled between January 2005 and May 2009.
AHI is defined as a negative or indeterminate enzyme immunoassay (EIA) or a negative
HIV RNA test within 45 days of enrollment plus a reproducibly detectable HIV by
amplification methods. Baseline genotypes were obtained on all participants at enrollment.
Virologic failure was defined as: i) failure to suppress to <200 copies/mL by week 24 [22],
and ii) for participants with the potential to reach week 48, HIV RNA >50 copies/mL at
week 48. HIV RNA was measured using the Roche Amplicor Monitor ultrasensitive assay,
version 1.5 with a 50 copies/mL lower limit of detection prior to December 2008, and
thereafter using the Abbott RealTime HIV-1 assay with a 40 copies/mL lower limit of
detection. Acute retroviral syndrome (ARS) symptom data were collected via standardized
forms and included fever, headache, night sweats, weight loss, myalgias, arthralgias, fatigue,
rash, odynophagia, lymphadenopathy, oral candidiasis, mouth ulcers/sores, cough, loss of
appetite, nausea/vomiting, diarrhea and abdominal pain in the 8 weeks before AHI
diagnosis. Estimated-date-of-infection was calculated as 14 days prior to onset of symptoms
consistent with ARS [23]. The level of circulating CD8+HLA-DR+CD38+ T cells was
measured in fresh blood samples collected in EDTA tubes by flow-cytometry. The samples
will be collected at enrollment, six month post-initiation of therapy, and every six months
thereafter. In order to identify the circulating activated CD8+ cells, we used the following
panel of antibody: aCD3-PerCP; aCD8_FITC; aHLA-DR-APC: and aCD38-PE. The
samples were acquired using a 4-color Calibur flow cytometer instrument (Becton
Dickinson, San Jose, CA). The frequency of activated CD8+ T-cells defined as CD38+HLA-
DR+ cells measured by flow cytometry was compared between AHI participants and a
seronegative cohort using two sample T-test statistics. The study was approved by the
University of North Carolina at Chapel Hill (UNC) and Duke University Institutional
Review Boards. All participants provided written informed consent.
The historical chronic cohort is composed of a random sample of 92 chronically-infected
participants of naïve ART studies with efavirenz-based regimens, who provided written
informed consent to participate in the UNC Center for AIDS Research (CFAR), Clinical and
Research Database and the Duke University Medical Center HIV Samples Repository and
Database. Individuals in the historical cohort must have initiated an efavirenz-based regimen
with a dual NRTI backbone of tenofovir/emtricitabine, zidovudine/lamivudine or abacavir/
lamivudine and had HIV RNA measured within 30 days prior to ART start.
We examined time-to-viral-suppression among AHI participants in relation to baseline
characteristics using the Kaplan Meier method and multivariate Cox proportional hazards
regression. Time-to-viral-suppression was defined as the time to HIV RNA <50 copies/mL
after ART initiation. Exposures included baseline CD8+ cell activation, duration from
estimated-date-of-infection until treatment, and baseline HIV RNA level. We compared
time-to-viral-suppression between AHI participants and chronically-infected participants. In
both analyses, participants were censored if they stopped treatment, were lost to follow-up
or at their last visit if before week 24. The Kaplan Meier method was used to compare time-
to-viral-suppression between groups. Multivariate proportional hazards regression was used
to estimate hazard ratios, controlling for baseline HIV RNA, CD4 count and age. The final
model was built using backwards elimination with a 10% change in estimate criteria for
retaining confounding variables, and was adjusted for baseline log10HIV RNA and CD4
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count. Log-rank tests were used to test differences in suppression times between groups. We
performed a linear test for trend to determine factors associated with baseline frequency of
activated CD8+ cells. Adjusted hazard ratios and 95% confidence intervals were calculated
for activated CD8+ cells, controlling for baseline log HIV RNA.
We fit linear mixed effects regression models with random intercepts and slopes to examine
the effect of treatment on HIV RNA levels among and between AHI participants and
chronically-infected patients. We extended the mixed effects model allowing for an
inflection point to separate the initial and subsequent phases of decay in plasma HIV RNA
levels, and to account for left and right censoring due to lower and upper detection limits.
We also tested a model in which the end of phase I decay was modeled independently in
acute and chronic participants, resulting in a very similar duration of phase I decay and
similar HIV RNA levels at the inflection point. The model with a single inflection point
from 1st to 2nd phase decay for acutely- and chronically-infected patients resulted in a better
fit with the data. Time zero was defined as the date of ART initiation. Only chronically-
infected participants with baseline HIV RNA levels between −30 days and time zero and at
least one HIV RNA measurement within 14 days following ART initiation were included in
this analysis. Only AHI participants with a baseline HIV RNA level between −7 days and
time zero, and at least one additional HIV RNA measurement within 14 days of starting
ART were included. HIV RNA levels until a participant stopped an efavirenz-containing
regimen or reached week 48 were included. For two piece models, we assumed the same
estimated inflection point at 10 days for both acute and chronic participants. The three
random effects considered can be summarized as follows: (1) random intercepts, ai; (2)
random slopes from time zero until the inflection point, bi; and (3) random slopes from the
inflection point until the participant’s last HIV RNA measurement or end date, ci. All
analyses were conducted using SAS version 9.2 (SAS institute, Cary, NC). The finite sample
corrected Akaike Information Criterion (AICC), provided from SAS NLMIXED output as a
measure of goodness-of-fit (the smaller the AICC, the better the fit.) was used to select
whether to include an inflection point and the number of random effects. Detailed
description of the linear mixed effects regression models and the likelihood function for the
lognormal random effects model with left and right censoring is available (see Appendix).
Results
Sixty-one acutely-infected participants enrolled on study. The median age was 30 years,
most (89%) were men who have sex with men (MSM), and approximately half were white
(Table 1). Ninety-eight percent reported at least one ARS-associated symptom, with a
median of 8 (range 0–15) symptoms reported. In the 8 weeks preceding AHI diagnosis, 15%
had a documented sexually transmitted infection.
Only 4 (7.8%) of 51 participants with the potential to reach week 24 met criteria for
treatment failures. One participant was lost to follow-up, one terminated ART at week 12,
another demonstrated isolated, low viremia at week 24 preceded and followed by viral
suppression, and one had a HIV RNA level >200 copies/mL but <1000 copies/mL at week
24 (see below). Among the 4 treatment failures, none had baseline resistance to efavirenz,
and only one had mutations (69S and 70R) associated with NRTI resistance. Among 41
participants with the potential to reach week 48, 35 (85.4%) demonstrated suppression to
<50 copies/mL. Of 6 participants without documented suppression, 3 were lost to follow-up,
2 demonstrated isolated viremia preceded and followed by durable viral suppression, and
one had a HIV RNA level of 54 copies/mL.
Among 61 participants enrolled, 9 (14.8 %) stopped or changed their initial study regimen.
One discontinued ART at week 12, and was followed off treatment. Another participant
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interrupted ART due to dizziness after week 24 following suppression to <50 copies/mL, but
re-suppressed after restarting the study regimen. Two other participants discontinued
efavirenz due to side effects; one secondary to rash and another with depressed mood,
fatigue and gastrointestinal upset. Both participants switched to FDC tenofovir/emtricitabine
with a boosted PI. One participant underwent ART intensification with lopinavir/ritonavir
added to the study regimen due to HIV RNA of 1489 copies/mL at week 8, and was
switched to tenofovir/emtricitabine, ritonavir-boosted darunavir and zidovudine with HIV
RNA of 376 copies/mL at week 24 without additional genotype data due to low viremia, and
subsequently suppressed to <50 copies/mL at week 36.
Four of 61 (6.6%) participants had at least one mutation on baseline genotype associated
with resistance to NNRTIs. Two participants had the K103N mutation, one had the K103S
and one demonstrated the Y181C mutation. All four subjects were switched to FDC
tenofovir/emtricitabine with ritonavir-boosted atazanavir. Two participants with baseline
NNRTI resistance suppressed to <200 copies/mL at week 8 following genotype-guided
change in ART; one was subsequently lost to follow-up before week 48, and the other
maintained HIV RNA <50 copies/mL at week 48. The other 2 subjects with baseline
resistance suppressed to <200 copies/mL by week 16 following a change in their ART
regimen, and maintained HIV RNA <50copies/mL at week 48.
The median initial HIV-1 RNA level for AHI participants was 173,150 copies/mL (range
399–14,538,865), and the median highest observed HIV RNA level was 707,910 copies/mL
(range 12,803–84,545,454). The median delay from estimated-date-of-infection to ART start
was 43 days (range 22–103), and the median time from ART initiation to viral suppression
<50 copies/mL was 93 days (range 14–337) (Figure 1A). Higher viremia at ART initiation
(p=0.02) (Figure 1A), but not time from estimated-date-of-infection to ART start (p= 0.86)
was associated with a longer time-to-viral-suppression.
Baseline characteristics of the AHI and chronically-infected cohorts are listed in Table 2.
The chronically-infected cohort was older, and had fewer MSM (39% versus 80% among
AHI participants.) Median CD4 count at ART initiation was 180 cells/mm3 among
chronically-infected participants versus 541 cells/mm3 among AHI participants. Median
HIV RNA level at ART initiation was higher among the AHI cohort versus the chronic
cohort (5.2 versus 4.8 log10 copies/mL, respectfully.) AHI participants achieved viral
suppression more rapidly than chronically-infected participants in unadjusted analysis
(HR=1.41; 95%CI: 0.97, 2.06) (Figure 1B), a trend which remained after adjustment for
baseline log10 HIV RNA and CD4 count (adjusted HR=1.32; 95%CI: 0.79, 2.23) (Figure
1B).
We performed a mixed model analysis of viral dynamics using data from 57 of 61 AHI
participants (4 did not have HIV RNA measured within 14 days of ART start) and 33 of 92
chronically-infected participants that met HIV RNA sampling criteria. An AICC goodness-
of-fit test indicated the model with the best fit included an inflection point and all three
random effects (Figure 2). The inflection point was estimated to be 10 days (95% CI: 9, 11
days) after ART initiation. The mean plasma HIV RNA of AHI participants and chronically-
infected individuals at the inflection point were similar, log10HIV RNA=3.2 (1,471 copies/
ml) and log10HIV RNA=3.1 (1,254 copies/ml), respectively. The mean slope of log10HIV
RNA during the first phase of decay was −2.1 over 10 days in both AHI and chronically-
infected participants.
The log10HIV RNA mean slope for both AHI and chronically-infected participants after the
inflection point was negative, but much more gradual. During phase II decay, the slope of
log10HIV RNA per week was significantly steeper for AHI versus chronically-infected
Gay et al. Page 5













participants, −0.14 (95%CI: −0.15, −0.13) log10 versus −0.094 (95%CI: −0.11, −0.08) log10
decrease per week, respectively (p=0.02). Statistical analysis excluding 14 AHI participants
without HIV RNA measured on the exact date of ART start were essentially the same
(results not shown). Variance estimates reflect a high level of heterogeneity between
participants, the largest of which was the variation between phase I slopes.
The median frequency of CD8+CD38+HLADR+ T-cells among AHI participants at baseline
was 67% (range 40–95) (Figure 3A), and was significantly higher compared with a median
frequency of 9% (range 3–22) among a seronegative cohort (Figure 3B). High frequency of
activated CD8+ T-cells among AHI participants was associated with lower baseline CD4
count (p=0.05) and higher baseline HIV RNA (p=0.03). However, frequency of
CD8+CD38+HLADR+ T-cells >67% was not significantly associated with longer time-to-
viral-suppression (Adjusted HR=0.74; 95%CI: 0.33, 1.59). There was a substantial and
significant decline in immune activation as measured by CD8+CD38+HLADR+ frequency
from baseline to week 12 among AHI participants on therapy (p<0.0001) compared to
untreated acute patients, but levels remained significantly higher than uninfected controls
(p<0.0001) (Figure 3B).
Discussion
Our findings indicate that once daily emtricitabine/tenofovir/efavirenz initiated during AHI
achieves rapid and sustained HIV suppression despite initial high viremia. Ninety-two
percent of AHI participants suppressed to <200 copies/mL by week 24, and 85% with the
potential to reach week 48 remained suppressed. Our work supports prior studies of ART
efficacy in AHI. In one study, all 12 acutely-infected participants suppressed to <50 copies/
mL by week 24 [24], and 94% of AHI participants remained suppressed ≤50 copies/mL at
one year in another study [25]. In further work, 97% of subjects with acute or early HIV
infection suppressed by a median of 11 weeks, and there was no difference in time-to-
suppression between PI- and NNRTI-based regimens [26].
The prevalence of NNRTI resistance in our cohort was low, and did not prevent rapid and
sustained viral suppression with ART modification based on baseline genotype. This result
suggests that prompt initiation of ART during AHI need not be delayed pending baseline
genotype information, but supports obtaining genotypes on all AHI patients, to guide rapid
ART changes if needed. A one-pill, once-a-day regimen facilitated rapid initiation of ART
in out AHI participants. However, our study cannot address the long-term impact of initial
NNRTI-based therapy with prompt ART modification per resistance information versus a
more complex initial regimen less likely to be affected by baseline resistance.
Not surprisingly, higher HIV RNA levels at ART initiation were associated with longer
time-to-viral-suppression among AHI participants. However, given substantially higher
viremia at or prior to ART initiation among AHI participants, a trend towards a shorter time
to virologic suppression among AHI versus chronic participants was unexpected. We used
linear mixed effects regression models to further explore viral decay on therapy between
acutely and chronically-infected individuals. This analysis confirmed initial rapid decline in
viremia following ART initiation during AHI similar to the declines in chronic infection.
The model with the best fit incorporated an estimated inflection point at day 10 for both
acute and chronic participants, consistent with a phase I and phase II decay. Similar HIV
RNA levels at the inflection point for both acute and chronic participants suggest the size of
the pool of cells comprising second (and later) phases of decay is also similar. We
demonstrated a steeper decline in HIV RNA in phase II decay among AHI participants
versus chronic participants, supporting our finding of earlier time-to-viral-suppression
among AHI participants. A shorter half-life of T cells in pre-integration latency in AHI and/
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or lower concentrations of infected longer-lived cells (i.e. macrophages) due to the shorter
duration of infection in AHI compared to chronic infection are possible explanations. The
shorter half-life of pre-integration T cells may be due to the higher activation state during
AHI and more rapid division of these cells. Finally, more effective HIV specific immune
responses in AHI may also contribute to a shorter half-life.
Our findings support prior work showing a two phase HIV RNA decline with acute infection
[27], and similar first phase decay among AHI versus chronically-infected participants [27–
29]. The latter suggests the half-life of infected, activated T cells is similar in acute and
chronic patients during phase I decay. Our results are in contrast with one study that showed
a, slower HIV RNA decline on ART in primary versus chronic HIV infection, which was
attributed to immature immune responses resulting in slower decay of virion-producing
infected cells [30]. Our results showing a rapid decline in HIV RNA with ART are
consistent with reports of strong and early HIV specific T-cell responses during AHI [27,
31, 32].
The mixed model analysis was limited by the small group of chronically-infected
participants who met HIV RNA criteria from ART initiation, and the timing of HIV RNA
sampling in the immediate period following treatment among both acutely- and chronically-
infected participants. Nevertheless, our findings of a steep viral decline following ART
initiation during AHI and sustained efficacy after suppression may be relevant to the concept
of ART as a prevention strategy [33]. During this same time period we also followed 12
acutely-infected individuals who declined ART during AHI. These individuals initiated
ART a median of 384 days (range 87–827) from the date of AHI diagnosis consistent with
the results of other groups [34]. Therefore, acutely infected individuals presenting with
symptoms may be spared only 1–2 years of ART; a fact that may weigh in the balance when
considering initiation of ART in acutely infected individuals.
Our work confirms high levels of immune activation among AHI participants compared to
seronegative individuals [35]. Baseline frequency of CD8+CD38+HLADR+ T-cells was
associated with lower baseline CD4 count and higher baseline HIV RNA possibly related to
the loss of immune regulation as suggested by the high level of pro-inflammatory cytokines
detected during acute infection [36]. We hypothesized that immune activation might affect
time-to-viral-suppression; however, after controlling for baseline HIV RNA, CD4 count and
age, baseline frequency of CD8+CD38+HLADR+ T-cells was not associated with increased
time-to-viral-suppression or nadir CD4 count. In contrast, another study found that a more
rapid time-to-viral-suppression to <50 copies/mL was associated with higher frequency of
activated CD8+ T-cells, as well as higher baseline CD4 count (p<0.001) and lower viremia,
after adjustment for age and gender [37]. Our results may suggest a different biological
relevance for activated CD8 T cells at ART initiation during AHI, when activated CD8
subsets may have a more critical role in controlling viral replication in the setting of
relatively preserved CD4 counts, as generally seen in AHI.
Although there are potential risks with NNRTI-based therapy in AHI, our results
demonstrate that acutely-infected patients, many from difficult social backgrounds and with
substantial barriers to treatment (distance-to-care, young age, MSM-related stigma) are
rapidly suppressed with simple and easily administered treatment. We feel our findings lend
support to the use of ART during AHI given demonstrated efficacy, and the high retention-
in-care and on study. Our findings also endorse the use of a once daily, co-formulated
NNRTI-based regimen, used in conjunction with baseline genotype data and appropriate
treatment adjustment if needed.
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Time to viral load suppression among acutitely-infected participants who initiated
antiretroviral therapy during acute HIV infection compared with chronically infected
patients starting an efavirenz-based regimen. The black line in Figure 1A shows the time-to-
viral-suppression to <50 copies/mL among all acutely infected participants started on
antiretroviral therapy during the acute period. The blue and red lines show the time-to-viral-
suppression <50 copies/mL stratified by baseline HIV RNA levels among acutely-infected
subjects who started antiretroviral therapy. Figure 1B shows the comparison of time-to-
viral-suppression with a NNRTI-based regimen between participants starting antiretroviral
therapy during acute HIV infection and chronically-infected participants starting treatment
during established HIV infection.
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Estimates of log10HIV RNA from a nonlinear mixed model from 0 to 11 months following
ART initiation among acutely- and chronically-infected participants with one inflection
point at 10 days.
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Figure 3A shows immune activation dynamics among acutely-infected participants from the
time of antiretroviral initiation. Figure 3B compares levels of immune activation among
acutely-infected individuals by time since antiretroviral initiation with a seronegative cohort.
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Table 1
Baseline demographic and clinical characteristics of participants with acute HIV infection.
Total N = 61
Demographic Characteristics N (%) or Median (range)
Age (years) 30 (18–66)
Sexual risk groupa
    Female 6 (10)
    Heterosexual Male 6 (10)
    MSM 49 (80)
Race/ethnicity
    White, Non-Hispanic 32 (52)
    White, Hispanic 1 (2)
    African American 27 (44)
    Asian 1 (2)
Symptoms 60 (98)
STD ≤8 weeks prior to diagnosis 9 (15)
Seronegative at ART start 5 (8)
Number of symptoms 8 (0–15)
Viral load (copies/mL)
    Initial 173,150 (399–14,538,865)
    Peak 707,910 (12,803–84,545,454)
CD4 (cells/mm3)
    Baseline CD4 (cells/mm3) 541 (13–1012)
    Nadir CD4 (cells/mm3) 425 (13–851)
Time, days
    Infection to ART 43 (22–103)
    Diagnosis to ART start 19 (4–41)
    ART start to viral load <50 copies/mLc 93 (14–337)
    ART start to viral load <200 copies/mL 75 (10–239)
a
Based on sex of reported partners
b
Peak HIV RNA levels prior to study enrollment were included when available
c
54 subjects had suppressed to VL<50 and VL<400 and were included in analysis.
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Table 2
Acute vs. Historical Chronic Cohort
Acutes Chronics
N % N %
Total 61 100% 92 100%
HIV RNA <50 copies/mL by week 24 48 79% 66 72%
Sexual Risk Group
     Female 6 10% 23 25%
     Heterosexual Male 6 10% 12 13%
     MSM 49 80% 34 37%
     Unknown - - 23 25%
Race/Ethnicity
     White, Non-Hispanic 32 52% 29 32%
     Other 29 48% 63 68%
IVDU 2 3.2% 3 3%
Median IQRb Median IQR
Age at ART start 30 (24–39) 44 (34–53)
Time from diagnosis to ART start 19 (14–24) 138a (71–398)
Log10 HIV RNA at ART start 5.2 (4.5–5.8) 4.8 (4.5–5.4)
CD4 at ART start 541 (343–644) 184 (52–311)




IQR = interquartile range
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